AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer

作者：Jung‐Yun Lee, Sathana Boonyapipat, Guangwen Yuan, Hee Seung Kim, Jeong‐Won Lee, Li Wang, Tao Wang, Danbo Wang, Desheng Yao, Hu Liu, Chih‐Long Chang, Т. Андабеков, Xiang Zhang, W. Wang, Yong‐Man Kim, Ivan Sinielnikov, Kai Wang, Yujuan Gao, Xiyan Mu, Lingying Wu · 发表于：Gynecologic Oncology · 年份：2025 · DOI：10.1016/j.ygyno.2025.04.579 · 被引用次数：8 · 研究领域：Endometrial and Cervical Cancer Treatments、Cancer Immunotherapy and Biomarkers、HER2/EGFR in Cancer Research